Eagle Pharmaceuticals, Inc. (EGRX)

Eagle Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	257.55	316.61	171.55	187.8	195.89	213.31
Revenue Growth (YoY)	-5.38%	84.56%	-8.66%	-4.13%	-8.17%	-9.88%
Cost of Revenue	77.68	94.94	42.18	45.47	60.9	61.92
Gross Profit	179.88	221.67	129.37	142.34	135	151.4
Selling, General & Admin	103.22	106.63	75.32	78.6	76.37	60.51
Research & Development	35.65	34.09	51.28	30.79	36.81	44.42
Other Operating Expenses	0	0	0	0	0	10.62
Operating Expenses	138.87	140.71	126.6	109.38	113.18	115.54
Operating Income	41.01	80.96	2.77	32.95	21.82	35.85
Interest Expense / Income	6.09	4.05	1.64	2.58	2.69	2.74
Other Expense / Income	5.74	15.48	5.68	7.7	-2.87	-0.92
Pretax Income	29.17	61.43	-4.55	22.68	22	34.04
Income Tax	17.22	25.79	4.08	10.69	7.69	2.14
Net Income	11.95	35.64	-8.63	11.99	14.31	31.9
Net Income Growth	-47.57%	-	-	-16.24%	-55.14%	-38.58%
Shares Outstanding (Basic)	13	13	13	13	14	15
Shares Outstanding (Diluted)	13	13	13	14	14	15
Shares Change	2.48%	0.11%	-5.23%	-2.60%	-7.46%	-3.96%
EPS (Basic)	0.92	2.76	-0.66	0.89	1.04	2.16
EPS (Diluted)	0.91	2.73	-0.66	0.87	1.01	2.09
EPS Growth	-48.59%	-	-	-13.86%	-51.67%	-36.09%
Free Cash Flow	-9.39	50.52	27.9	48.75	55.21	52.25
Free Cash Flow Per Share	-0.72	3.91	2.14	3.62	4.01	3.54
Gross Margin	69.84%	70.01%	75.41%	75.79%	68.91%	70.97%
Operating Margin	15.92%	25.57%	1.61%	17.55%	11.14%	16.81%
Profit Margin	4.64%	11.26%	-5.03%	6.38%	7.31%	14.96%
Free Cash Flow Margin	-3.65%	15.96%	16.26%	25.96%	28.18%	24.50%
Effective Tax Rate	59.04%	41.98%	-	47.13%	34.93%	6.27%
EBITDA	57.18	78.75	1.89	30.02	29.34	40.44
EBITDA Margin	22.20%	24.87%	1.10%	15.98%	14.98%	18.96%
Depreciation & Amortization	21.92	13.27	4.81	4.77	4.65	3.67
EBIT	35.26	65.48	-2.91	25.25	24.68	36.77
EBIT Margin	13.69%	20.68%	-1.70%	13.45%	12.60%	17.24%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).